相关实验视频
Updated: Mar 13, 2026

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.6K
[在类风湿性关节炎中使用Janus 激酶抑制剂或生物疗法?]
1Service de rhumatologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
Revue medicale suisse
|March 11, 2026
概括
在Janus激酶抑制剂 (JAKi) 和治疗类风湿性关节炎的生物药物之间做出选择,需要权衡相似的疗效与潜在风险. 现实世界的数据表明,JAKi对心血管安全,但瘤风险需要进一步研究,以进行个性化治疗决策.
科学领域:
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 常规疗法在类风湿性关节炎 (RA) 患者中经常失败,需要在Janus激酶抑制剂 (JAKi) 和生物药物之间做出选择.
- 无论是JAKi还是生物药物都在治疗RA方面表现出相似的疗效,随机试验和现实世界的数据证明了这一点.
研究的目的:
- 在常规治疗后的类风湿性关节炎患者中,比较JAK抑制剂与生物药物的疗效和安全性.
- 根据最近的研究结果和现实世界的证据,评估与JAK抑制剂相关的心血管和瘤风险.
主要方法:
- 随机对照试验和现实研究的综述,比较RA中的JAKi和生物药物.
- 分析ORAL监测研究和有关不良事件的国际患者登记册的数据.
- 对个性化治疗选择的风险益处概况的评估.
主要成果:
- 在类风湿性关节炎治疗中,JAKi和生物药物的有效性相似.
- 口腔监测研究表明,高风险人群中JAKi存在潜在的心血管和瘤风险.
- 在现实实践中,国际注册表并不总是显示JAKi的心血管风险增加,而瘤学数据仍然混杂.
结论:
- 在常规治疗失败后,对于类风湿性关节炎的治疗决策应该是个性化的.
- 考虑患者特定的风险概况,偏好以及不受控制的炎症的影响至关重要.
- 持续评估JAKi的安全性,特别是瘤风险,对于知情的临床实践是必要的.
相关概念视频
The JAK-STAT Signaling Pathway
13.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
692
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
692
Inflammatory Bowel Disease IV: Pharmacological Management
884
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
884
Rheumatic Heart Disease III: Medical Management
450
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
450
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
615
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
615
Antihypertensive Drugs: Direct Renin Inhibitors
1.7K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.7K

